For research use only. Not for therapeutic Use.
Cladribine（Cat No.:I003531）is a medication that functions as an adenosine deaminase inhibitor. It is primarily used to treat two conditions: hairy cell leukemia (HCL) and multiple sclerosis (MS). In HCL, cladribine works by suppressing the production of abnormal white blood cells. In MS, it modulates the immune system to reduce the frequency of relapses. Cladribine is available in oral and injectable forms, and its use requires careful monitoring due to potential side effects, particularly effects on the immune system and bone marrow suppression.
| Catalog Number | I003531 |
| CAS Number | 4291-63-8 |
| Synonyms | (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol |
| Molecular Formula | C10H12ClN5O3 |
| Purity | ≥95% |
| Target | DNA Synthesis |
| Solubility | DMSO: ≥ 48 mg/mL |
| Storage | -20°C |
| IUPAC Name | (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol |
| InChI | InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1 |
| InChIKey | PTOAARAWEBMLNO-KVQBGUIXSA-N |
| SMILES | C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O |
| Reference | </br>1:A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma. Wei Z, Li J, Cheng Z, Yuan L, Liu P.J Thorac Dis. 2017 Apr;9(4):1081-1092. doi: 10.21037/jtd.2017.03.81. PMID: 28523163 </br>2:Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LC-MS/MS in human cancer cells. Puy JY, Jordheim LP, Cros-Perrial E, Dumontet C, Peyrottes S, Lefebvre-Tournier I.J Chromatogr B Analyt Technol Biomed Life Sci. 2017 May 15;1053:101-110. doi: 10.1016/j.jchromb.2017.03.024. Epub 2017 Mar 24. PMID: 28415014 </br>3:Purpuric exanthema in a patient with hairy cell leukemia treated with cladribine and allopurinol. Espinosa Lara P, Quirós Redondo V, Aguado Lobo M, Jiménez-Reyes J.Ann Hematol. 2017 Apr 8. doi: 10.1007/s00277-017-2992-z. [Epub ahead of print] No abstract available. PMID: 28391438 </br>4:Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis. Savic RM, Novakovic AM, Ekblom M, Munafo A, Karlsson MO.Clin Pharmacokinet. 2017 Mar 2. doi: 10.1007/s40262-017-0516-6. [Epub ahead of print] PMID: 28255849 </br>5:Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. Goyal G, Shah MV, Call TG, Litzow MR, Hogan WJ, Go RS.JAMA Oncol. 2017 Mar 2. doi: 10.1001/jamaoncol.2017.0041. [Epub ahead of print] PMID: 28253394 </br>6:Successful treatment of histiocytic sarcoma with cladribine and high-dose cytosine arabinoside in a child. Iwabuchi H, Kawashima H, Umezu H, Takachi T, Imamura M, Saitoh A, Ogose A, Imai C.Int J Hematol. 2017 Feb 28. doi: 10.1007/s12185-017-2202-8. [Epub ahead of print] PMID: 28247189 </br>7:Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia. Woelich SK, Braun JT, Schoen MW, Ramlal R, Freter CE, Petruska PJ, Lionberger JM.Anticancer Res. 2017 Feb;37(2):713-717. PMID: 28179321 </br>8:Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. De Stefano N, Giorgio A, Battaglini M, De Leucio A, Hicking C, Dangond F, Giovannoni G, Sormani MP.Mult Scler. 2017 Jan 1:1352458517690269. doi: 10.1177/1352458517690269. [Epub ahead of print] PMID: 28140753 </br>9:Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. Pluta A, Robak T, Wrzesien-Kus A, Katarzyna Budziszewska B, Sulek K, Wawrzyniak E, Czemerska M, Zwolinska M, Golos A, Holowiecka-Goral A, Kyrcz-Krzemien S, Piszcz J, Kloczko J, Mordak-Domagala M, Lange A, Razny M, Madry K, Wiktor-Jedrzejczak W, Grosicki S, Butrym A, Kuliczkowski K, Warzocha K, Holowiecki J, Giebel S, Szydlo R, Wierzbowska A.Am J Hematol. 2017 Apr;92(4):359-366. doi: 10.1002/ajh.24654. Epub 2017 Feb 13. PMID: 28103640 </br>10:Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine. Alstadhaug KB, Fykse Halstensen R, Odeh F.J Clin Virol. 2017 Mar;88:17-20. doi: 10.1016/j.jcv.2016.12.005. Epub 2016 Dec 14. PMID: 28095350 |
